Related Experiment Video
Updated: Apr 23, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Dysregulated serum response factor triggers formation of hepatocellular carcinoma
Stefan Ohrnberger1, Abhishek Thavamani, Albert Braeuning
1Department for Molecular Biology, Interfaculty Institute of Cell Biology, Tuebingen University, Germany.
Unlabelled:
The ubiquitously expressed transcriptional regulator serum response factor (SRF) is controlled by both Ras/MAPK (mitogen-activated protein kinase) and Rho/actin signaling pathways, which are frequently activated in hepatocellular carcinoma (HCC). We generated SRF-VP16iHep mice, which conditionally express constitutively active SRF-VP16 in hepatocytes, thereby controlling subsets of both Ras/MAPK- and Rho/actin-stimulated target genes. All SRF-VP16iHep mice develop hyperproliferative liver nodules that progresses to lethal HCC. Some murine (m)HCCs acquire Ctnnb1 mutations equivalent to those in human (h)HCC. The resulting transcript signatures mirror those of a distinct subgroup of hHCCs, with shared activation of oncofetal genes including Igf2, correlating with CpG hypomethylation at the imprinted Igf2/H19 locus.
Conclusion:
SRF-VP16iHep mHCC reveal convergent Ras/MAPK and Rho/actin signaling as a highly oncogenic driver mechanism for hepatocarcinogenesis. This suggests simultaneous inhibition of Ras/MAPK and Rho/actin signaling as a treatment strategy in hHCC therapy.
Insights
Serum response factor (SRF) drives hepatocellular carcinoma (HCC) through Ras/MAPK and Rho/actin signaling. Inhibiting both pathways may offer a novel HCC treatment strategy.
Area of Science:
- Molecular biology
- Oncology
- Hepatology
Background:
- Serum response factor (SRF) is a key regulator of genes involved in cell proliferation and survival.
- Ras/MAPK and Rho/actin signaling pathways are frequently activated in hepatocellular carcinoma (HCC).
- Understanding the role of SRF in HCC pathogenesis is crucial for developing effective therapies.
Purpose of the Study:
- To investigate the role of constitutively active SRF in hepatocarcinogenesis.
- To determine if SRF activation can drive the development of HCC.
- To explore the molecular mechanisms by which SRF contributes to HCC development.
Main Methods:
- Generation of SRF-VP16iHep mice with conditional expression of active SRF in hepatocytes.
- Analysis of liver nodules and HCC development in these mice.
- Transcriptomic and epigenomic analysis of murine and human HCCs.
Main Results:
- SRF-VP16iHep mice developed hyperproliferative liver nodules progressing to lethal HCC.
- Murine HCCs acquired Ctnnb1 mutations, mirroring human HCC.
- Transcriptional profiles of murine HCCs resembled a subgroup of human HCCs with activated oncofetal genes and Igf2/H19 hypomethylation.
Conclusions:
- Convergent Ras/MAPK and Rho/actin signaling driven by SRF is a potent oncogenic mechanism in hepatocarcinogenesis.
- Simultaneous inhibition of Ras/MAPK and Rho/actin signaling represents a potential therapeutic strategy for HCC.
More Related Videos
Related Concept Videos
Cirrhosis II: Pathophysiology
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
The Ras Gene
Ras is a...
Hepatitis
Cell Specific Gene Expression

